{
    "eid": "2-s2.0-85013677371",
    "title": "Sunrise in melanoma management: Time to focus on melanoma burden in Asia",
    "cover-date": "2017-12-01",
    "subject-areas": [
        {
            "$": "Oncology",
            "@code": "2730"
        }
    ],
    "keywords": [],
    "authors": [
        "John Wen Cheng Chang"
    ],
    "citedby-count": 23,
    "ref-count": 43,
    "ref-list": [
        "Malignant melanoma in Taiwan: A prognostic study of 181 cases",
        "Skin Cancer (Japan).",
        "Clinical presentation, histology, and prognoses of malignant melanoma in ethnic Chinese: A study of 522 consecutive cases",
        "Staging and prognosis of cutaneous melanoma",
        "Skin cancer in asians part 2: Melanoma",
        "Treatment and outcomes of melanoma in acral location in korean patients",
        "Melanoma: Differences between asian and caucasian patients",
        "Statistical profiles of malignant melanoma and other skin cancers in Japan: 2007 Update",
        "A new understanding in the epidemiology of melanoma",
        "Ethnic differences among patients with cutaneous melanoma",
        "Melanoma Arising in African-, Asian-, Latino- and Native-American Populations",
        "Acral lentiginous melanoma: Incidence and survival patterns in the United States, 1986-2005",
        "Cutaneous melanoma: Taiwan experience and literature review",
        "A case-control study of melanomas of the soles and palms (Australia and Scotland)",
        "A clinicopathologic analysis of 177 acral melanomas in Koreans: Relevance of spreading pattern and physical stress",
        "The global burden of skin disease in 2010: An analysis of the prevalence and impact of skin conditions",
        "Human cutaneous melanoma; a review of NRAS and BRAF mutation frequencies in relation to histogenetic subclass and body site",
        "The role of BRAF V600 mutation in melanoma",
        "Incidence of BRAF Oncogene Mutation and Clinical Relevance for Primary Cutaneous Melanomas",
        "Prevalence of BRAF and NRAS mutations in cutaneous melanoma patients in Taiwan",
        "Prevalence of BRAF V600E mutation in Chinese melanoma patients: Large scale analysis of BRAF and NRAS mutations in a 432-case cohort",
        "BRAF mutations and KIT aberrations and their clinicopathological correlation in 202 Korean melanomas",
        "Frequency of BRAF mutation and clinical relevance for primary melanomas",
        "Prognostic and clinicopathologic associations of BRAF mutation in primary acral lentiginous melanoma in Korean patients: A preliminary study",
        "Clinical characteristics associated with BRAF, NRAS and KIT mutations in Japanese melanoma patients",
        "BRAF V600 mutations and pathological features in Japanese melanoma patients",
        "Somatic activation of KIT in distinct subtypes of melanoma",
        "KIT gene mutations and copy number in melanoma subtypes",
        "Characterization of KIT mutation in melanoma",
        "Phase II, open-label, single-arm trial of imatinib mesylate in patients with metastatic melanoma harboring c-Kit mutation or amplification",
        "Imatinib for melanomas harboring mutationally activated or amplified kit arising on mucosal, acral, and chronically sun-damaged skin",
        "The cell-cycle regulator CDK4: An emerging therapeutic target in melanoma",
        "Improved survival with ipilimumab in patients with metastatic melanoma",
        "Ipilimumab plus dacarbazine for previously untreated metastatic melanoma",
        "Pooled analysis of long-term survival data from phase II and phase III trials of ipilimumab in unresectable or metastatic melanoma",
        "Nivolumab in previously untreated melanoma without BRAF mutation",
        "Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): A randomised, controlled, open-label, phase 3 trial",
        "Pembrolizumab versus ipilimumab in advanced melanoma",
        "Cutaneous melanoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up",
        "Nivolumab: A review of its use in patients with malignant melanoma"
    ],
    "affiliation": [
        {
            "affiliation-city": "Taipei",
            "affilname": "Chang Gung Memorial Hospital",
            "affiliation-country": "Taiwan"
        },
        {
            "affiliation-city": "West Jakarta",
            "affilname": "Rumah Sakit Kanker Dharmais",
            "affiliation-country": "Indonesia"
        },
        {
            "affiliation-city": "Seoul",
            "affilname": "Yonsei Cancer Hospital",
            "affiliation-country": "South Korea"
        },
        {
            "affiliation-city": "Gurugram",
            "affilname": "Fortis Healthcare Ltd.",
            "affiliation-country": "India"
        },
        {
            "affiliation-city": "Singapore City",
            "affilname": "National Cancer Centre, Singapore",
            "affiliation-country": "Singapore"
        },
        {
            "affiliation-city": "Taipei",
            "affilname": "Mackay Memorial Hospital Taiwan",
            "affiliation-country": "Taiwan"
        },
        {
            "affiliation-city": "Bangkok",
            "affilname": "King Chulalongkorn Memorial Hospital",
            "affiliation-country": "Thailand"
        },
        {
            "affiliation-city": "Tokyo",
            "affilname": "National Cancer Center Hospital",
            "affiliation-country": "Japan"
        },
        {
            "affiliation-city": "Kuala Lumpur",
            "affilname": "University of Malaya Medical Centre",
            "affiliation-country": "Malaysia"
        },
        {
            "affiliation-city": "Beijing",
            "affilname": "Beijing Cancer Hospital",
            "affiliation-country": "China"
        },
        {
            "affiliation-city": "Hong Kong",
            "affilname": "Ying Chi Ho Anthony Clinic",
            "affiliation-country": "Hong Kong"
        },
        {
            "affiliation-city": "Hanoi",
            "affilname": "National Hospital of Dermatology and Venereology",
            "affiliation-country": "Viet Nam"
        },
        {
            "affiliation-city": "Manila",
            "affilname": "Cardinal Santos Medical Center",
            "affiliation-country": "Philippines"
        }
    ],
    "funding": [
        "Immuno-Oncology Center of Excellence at Chang-Gung Memorial Hospital",
        "John Wen-Cheng Chang and Chia-Yen Hung",
        "Bristol-Myers Squibb"
    ]
}